Nicholas Investment Partners LP Has $5.98 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL)

Nicholas Investment Partners LP trimmed its position in shares of Nuvalent, Inc. (NASDAQ:NUVL - Free Report) by 23.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,427 shares of the company's stock after selling 23,644 shares during the quarter. Nicholas Investment Partners LP owned 0.11% of Nuvalent worth $5,983,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Crowley Wealth Management Inc. acquired a new stake in shares of Nuvalent during the fourth quarter worth about $27,000. Quarry LP bought a new stake in shares of Nuvalent in the fourth quarter worth $39,000. US Bancorp DE bought a new position in Nuvalent in the fourth quarter valued at $90,000. KBC Group NV lifted its position in Nuvalent by 61.1% during the 4th quarter. KBC Group NV now owns 1,587 shares of the company's stock worth $124,000 after buying an additional 602 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Nuvalent by 13.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 2,618 shares of the company's stock valued at $205,000 after acquiring an additional 309 shares in the last quarter. Institutional investors own 97.26% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NUVL. UBS Group upgraded Nuvalent from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $110.00 target price on shares of Nuvalent in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $115.50.

Insider Transactions at Nuvalent

In related news, Director Matthew Shair sold 2,000 shares of the business's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $78.43, for a total value of $156,860.00. Following the completion of the sale, the director now directly owns 216,522 shares in the company, valued at $16,981,820.46. The trade was a 0.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO James Richard Porter sold 27,000 shares of the company's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $68.94, for a total value of $1,861,380.00. Following the completion of the transaction, the chief executive officer now directly owns 249,062 shares in the company, valued at approximately $17,170,334.28. This represents a 9.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 83,000 shares of company stock worth $6,185,150. 12.52% of the stock is owned by insiders.

Nuvalent Trading Down 3.0%

NUVL stock opened at $71.42 on Wednesday. Nuvalent, Inc. has a 1-year low of $55.54 and a 1-year high of $113.51. The business's 50 day simple moving average is $71.41 and its 200 day simple moving average is $80.13. The firm has a market capitalization of $5.11 billion, a PE ratio of -20.58 and a beta of 1.42.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.18) EPS for the quarter, missing analysts' consensus estimates of ($1.14) by ($0.04). During the same period in the previous year, the company earned ($0.69) EPS. As a group, sell-side analysts predict that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

Want to see what other hedge funds are holding NUVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvalent, Inc. (NASDAQ:NUVL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.